Lifecore Biomedical Reports 2025 Financial Results

Lifecore Biomedical, Inc. ( (LFCR) ) has released its Q4 earnings. Here is a breakdown of the information Lifecore Biomedical, Inc. presented to its investors.

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, with a strong focus on hyaluronic acid manufacturing. The company serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories.

Lifecore Biomedical reported its financial results for the fourth quarter and fiscal year 2025, highlighting a revenue of $128.9 million, which aligns with its full-year guidance. The company also announced the signing of nine new programs with new customers, indicating growth beyond its traditional ophthalmic therapeutics sector.

Key financial metrics showed a slight increase in annual revenues by 0.5% compared to the previous year, primarily driven by increased demand for hyaluronic acid manufacturing. However, the company faced a net loss of $38.7 million for the fiscal year, attributed to a decrease in CDMO revenues and increased interest expenses. Operational improvements were noted, with a reduction in selling, general, and administrative expenses during the fourth quarter.

Strategically, Lifecore has made significant strides by restructuring its organization under new leadership, enhancing efficiency, and expanding its customer base. The company is also transitioning its fiscal year-end to align with the calendar year, which is expected to improve reporting timeliness and operational efficiency.

Looking ahead, Lifecore remains committed to its growth strategies, aiming for a 12%+ revenue CAGR and expanding adjusted EBITDA margins over the mid-term. The company anticipates further operational efficiencies with the launch of a new ERP system in early 2026, positioning it for continued growth and profitability.